Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1151.08
ACHN's Cash to Debt is ranked higher than
77% of the 1275 Companies
in the Global Biotechnology industry.

( Industry Median: 69.96 vs. ACHN: 1151.08 )
ACHN' s 10-Year Cash to Debt Range
Min: 1.1   Max: No Debt
Current: 1151.08

F-Score: 3
Z-Score: 76.38
M-Score: -4.12
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -43.31
ACHN's ROE (%) is ranked higher than
71% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. ACHN: -43.31 )
ACHN' s 10-Year ROE (%) Range
Min: -199.15   Max: -52.4
Current: -43.31

-199.15
-52.4
ROA (%) -40.39
ACHN's ROA (%) is ranked higher than
69% of the 1279 Companies
in the Global Biotechnology industry.

( Industry Median: -27.24 vs. ACHN: -40.39 )
ACHN' s 10-Year ROA (%) Range
Min: -181.02   Max: -48.33
Current: -40.39

-181.02
-48.33
ROC (Joel Greenblatt) (%) -4570.28
ACHN's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 1249 Companies
in the Global Biotechnology industry.

( Industry Median: -347.70 vs. ACHN: -4570.28 )
ACHN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6066.62   Max: -465.75
Current: -4570.28

-6066.62
-465.75
Revenue Growth (3Y)(%) -100.00
ACHN's Revenue Growth (3Y)(%) is ranked higher than
54% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: -0.50 vs. ACHN: -100.00 )
ACHN' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: -42.3
Current: -100

EBITDA Growth (3Y)(%) 4.10
ACHN's EBITDA Growth (3Y)(%) is ranked higher than
82% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. ACHN: 4.10 )
ACHN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 4.1
Current: 4.1

0
4.1
EPS Growth (3Y)(%) 3.40
ACHN's EPS Growth (3Y)(%) is ranked higher than
82% of the 708 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. ACHN: 3.40 )
ACHN' s 10-Year EPS Growth (3Y)(%) Range
Min: -65.5   Max: 3.4
Current: 3.4

-65.5
3.4
» ACHN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ACHN Guru Trades in Q1 2014

Steven Cohen 43,533 sh (New)
Jean-Marie Eveillard Sold Out
Paul Tudor Jones Sold Out
Chuck Royce 500,000 sh (-15.25%)
» More
Q2 2014

ACHN Guru Trades in Q2 2014

Paul Tudor Jones 26,592 sh (New)
Steven Cohen 547,200 sh (unchged)
Chuck Royce 2,262 sh (-99.55%)
» More
Q3 2014

ACHN Guru Trades in Q3 2014

Jim Simons 897,300 sh (New)
Steven Cohen 1,048,100 sh (+91.54%)
Paul Tudor Jones 45,217 sh (+70.04%)
Chuck Royce 2,262 sh (unchged)
» More
Q4 2014

ACHN Guru Trades in Q4 2014

John Burbank 36,104 sh (New)
John Burbank 207,000 sh (unchged)
Jim Simons Sold Out
Chuck Royce Sold Out
Steven Cohen 621,900 sh (-40.66%)
Paul Tudor Jones 13,942 sh (-69.17%)
» More
» Details

Insider Trades

Latest Guru Trades with ACHN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2014-12-31 New Buy0.01%$9.76 - $15.49 $ 12.14-1%36104
Jean-Marie Eveillard 2014-03-31 Sold Out 0.01%$3.08 - $4.2 $ 12.14247%0
Jean-Marie Eveillard 2013-12-31 New Buy0.01%$2.43 - $3.46 $ 12.14319%600000
John Burbank 2012-12-31 Sold Out 0.24%$7.2 - $11.1 $ 12.1437%0
John Burbank 2012-09-30 New Buy0.24%$5.61 - $10.41 $ 12.1472%500000
George Soros 2012-06-30 Sold Out 0.04%$5.94 - $10.95 $ 12.1465%0
George Soros 2012-03-31 Reduce -50%0.09%$7.71 - $12.375 $ 12.1427%250000
George Soros 2011-12-31 Add 2132.14%0.16%$4.01 - $8 $ 12.1497%500000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 10.20
ACHN's P/B is ranked higher than
65% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. ACHN: 10.20 )
ACHN' s 10-Year P/B Range
Min: 0.79   Max: 17.77
Current: 10.2

0.79
17.77
EV-to-EBIT -17.80
ACHN's EV-to-EBIT is ranked higher than
63% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ACHN: -17.80 )
ACHN' s 10-Year EV-to-EBIT Range
Min: -25.5   Max: 0.6
Current: -17.8

-25.5
0.6
Current Ratio 11.73
ACHN's Current Ratio is ranked higher than
90% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. ACHN: 11.73 )
ACHN' s 10-Year Current Ratio Range
Min: 1.06   Max: 14.96
Current: 11.73

1.06
14.96
Quick Ratio 11.73
ACHN's Quick Ratio is ranked higher than
90% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. ACHN: 11.73 )
ACHN' s 10-Year Quick Ratio Range
Min: 1.06   Max: 14.96
Current: 11.73

1.06
14.96

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.56
ACHN's Price/Net Cash is ranked higher than
83% of the 1357 Companies
in the Global Biotechnology industry.

( Industry Median: 56.66 vs. ACHN: 10.56 )
ACHN' s 10-Year Price/Net Cash Range
Min: 0.82   Max: 12.7
Current: 10.56

0.82
12.7
Price/Net Current Asset Value 10.56
ACHN's Price/Net Current Asset Value is ranked higher than
82% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 36.79 vs. ACHN: 10.56 )
ACHN' s 10-Year Price/Net Current Asset Value Range
Min: 0.82   Max: 12.7
Current: 10.56

0.82
12.7
Price/Tangible Book 10.20
ACHN's Price/Tangible Book is ranked higher than
71% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 9.29 vs. ACHN: 10.20 )
ACHN' s 10-Year Price/Tangible Book Range
Min: 0.72   Max: 77.75
Current: 10.2

0.72
77.75
Earnings Yield (Greenblatt) -5.60
ACHN's Earnings Yield (Greenblatt) is ranked higher than
73% of the 1255 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. ACHN: -5.60 )
ACHN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 176.4   Max: 2697.4
Current: -5.6

176.4
2697.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ADA.Germany,
Achillion Pharmaceuticals Inc was incorporated on August 17, 1998 in Delaware. The Company is a biopharmaceutical company which focuses on the discoveries, develops and commercializes treatments for infectious diseases. Within the anti-infective market, it is currently focusing its efforts on developing commercially competitive, short-duration combination therapies for the treatment of chronic hepatitis C infection that are administered once-daily, orally, and without ribavirin. The Company competes with Abbvie, Astra-Zeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Enanta, Gilead, GlaxoSmithKline, Idenix, Johnson & Johnson, Presidio, Medivir, Merck, Novartis, Pfizer, Roche, Valeant and Vertex. The Company's drug candidates is subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, record keeping, labeling, marketing and distribution of drugs.
» More Articles for ACHN

Headlines

Articles On GuruFocus.com
Achillion Pharmaceuticals Stock Soars Following Successful Mid-Stage Hep C Drug Combo Trial Feb 10 2015 
Hall of Fame/ Hall of Shame: The Best and Worst Recommendations of 2014 Jan 09 2015 
Weekly CEO Sells Highlight: Achillion Pharmaceutical Inc, Protective Life Corp, Host Hotels & Resort Aug 25 2014 
Top 4 Insider Buys of Last Week Jun 10 2013 
comment on ACHN Mar 15 2013 
comment on ACHN Mar 09 2013 
Achillion Will Surge If New Drug Is Successful Apr 21 2012 
Weekly CEO Sells Highlight: Achillion Pharmaceuticals Inc, Monster Beverage Corp, CarMax Inc, and Im Jan 23 2012 
Weekly CEO Sells Highlight: UNH, LRY, ACHN, RPM Jan 16 2012 
Achillion Pharmaceuticals Inc. Reports Operating Results (10-Q) Oct 27 2010 

More From Other Websites
Biotech Making A Comeback - Here Is One Stock to Watch Feb 26 2015
Achillion Pharmaceuticals Announces Closing of Public Offering of Common Stock Feb 18 2015
Achillion Pharmaceuticals Announces Closing of Public Offering of Common Stock Feb 18 2015
Emergent BioSolutions Reports Positive Data on BioThrax - Analyst Blog Feb 16 2015
Acorda Beats Q4 Earnings Estimates; Ampyra Sales Grow - Analyst Blog Feb 13 2015
Ironwood Pharmaceuticals Cuts Loss on Higher Revenues - Analyst Blog Feb 13 2015
AbbVie Seeks Japanese Approval for HCV Cocktail Treatment - Analyst Blog Feb 12 2015
Hospira Beats on Q4 Earnings, Set to Be Acquired by Pfizer - Analyst Blog Feb 12 2015
The Zacks Analyst Blog Highlights: Achillion Pharmaceuticals, Gilead, AbbVie, Regeneron and Alkermes... Feb 12 2015
Achillion Pharmaceuticals Announces Pricing of Public Offering of Common Stock Feb 12 2015
Achillion Pharmaceuticals Announces Pricing of Public Offering of Common Stock Feb 11 2015
Celgene Up on Abraxane Getting Positive Recommendation - Analyst Blog Feb 11 2015
Gilead Sciences Shares Rise Amid Insider Buy, Conference Presentation Broadcast - Stocks in the News Feb 11 2015
Biotech Stock Roundup: Achillion Impresses with HCV Data, Regeneron 4Q Results Top Estimates -... Feb 11 2015
Zoetis Beats on Q4 Earnings, Provides In-Line 2015 Outlook - Analyst Blog Feb 11 2015
Achillion: Hep C Drug Discounting May Hurt Our Market Value, Stock Price Feb 11 2015
BUZZ-U.S. STOCKS ON THE MOVE-Genworth, Oncolytics, Bellatrix, Chico's Fas Feb 11 2015
JMP Securities Covers Mostly Good News From Pharma Pending More Visibility Feb 11 2015
ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 11 2015
Achillion Pharmaceuticals Announces Proposed Public Offering of Common Stock Feb 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK